Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors

ACTIVE NOT RECRUITING

Identifier: CI-TRIAL-00125136
Entity page: /trial/NCT05945823 ↗
Edges: 11

Neighbours: 3 cancers8 drugs
Drawn: 11 of 11 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,147 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors condition of …CONDITION_OFderived3 of 3
← condition of	Esophageal Adenocarcinoma registry condition “Esophageal Adenocarcinoma” mapped ONTOLOGY_EXACT	—	—	Esophageal Adenocarcinoma	1	Observed	clinicaltrials	graph →
← condition of	Esophageal Squamous Cell Carcinoma registry condition “Esophageal Squamous Cell Cancer” mapped ALIAS	—

Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors intervention of …INTERVENTION_OFderived8 of 8
← intervention of	Cisplatinsmall molecule registry intervention “Cisplatin” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Fluorouracilsmall molecule registry intervention “5-FU” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Futibatinibsmall molecule registry intervention “Futibatinib” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Irinotecansmall molecule registry intervention “Irinotecan” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Leucovorinsmall molecule registry intervention “Leucovorin” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Levoleucovorinsmall molecule registry intervention “Levoleucovorin” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Oxaliplatinsmall molecule registry intervention “Oxaliplatin” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →
← intervention of	Pembrolizumabmonoclonal antibody registry intervention “Pembrolizumab” (DRUG) mapped ALIAS	—	—	not mapped	1	Observed	clinicaltrials	graph →

Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors intervention of …INTERVENTION_OFderived8 of 8

← intervention of

Cisplatinsmall molecule

registry intervention “Cisplatin” (DRUG) mapped ALIAS

—

not mapped

Observed

clinicaltrials

graph →

← intervention of

Fluorouracilsmall molecule

registry intervention “5-FU” (DRUG) mapped ALIAS